Table 1.
Reference | Total Number | Age (Year) | LVEF% | Type of AF | Treatment Method | 1-Year Success Rate | Follow-Up Time (Success Rate) |
---|---|---|---|---|---|---|---|
[70] | 150 | 63.4±9.9 | 60.3±4.8 | Par | PFA | 66.2% | – |
[71] | 121 | 57.4±10.3 | 62.5±5.7 | Par | PFA | 78.5% | – |
[72] | 186 | 59.4±10.2 | 60.8±5.8 | Par | PFA | 78.9% | – |
[73] | 1568 | 64.5±11.5 | 60 | Par/Per | PFA | 78.1% | – |
[74] | 52 | 65±10 | 56±11 | Par/Per | PFA | – | 0.5 years (85%) |
[75] | 200 | 71 (62–77) | – | Par/Per | PFA | 80.3%(Par)/66.8%(Per) | – |
[76] | 191 | 69±12 | 60±10 | Par/Per | PFA | – | 0.5 years (94.2%) |
[77] | 138 | 67±12 | 52±10 | Par/Per | PFA | 90%(Par)/60%(Per) | – |
[70] | 150 | 66.0±9.0 | 57.6±6.4 | Per | PFA | 55.1% | – |
[78] | 45 | 67.1±10 | 56.5±11.2 | Per | PFA | – | 0.3 years (80%) |
[79] | 253 | 61±9 | 65.8±4.4 | Par | RFA | 82.7% | 2.1 years (79.6%) |
[80] | 25 | 59±9 | 58±6 | Par | RFA | 92% | – |
[81] | 100 | 60.0±10.1 | 58.9±8.0 | Par | RFA | 61.1% | – |
[82] | 260 | 58.3±8.7 | – | Par | RFA | – | 1.9 years (57.3%) |
[83] | 66 | 54.3±1.3 | 60.8±7 | Par | RFA | – | 2 years (45.5%) |
[84] | 146 | 56±9 | – | Par | RFA | 82.2% | 2 years (84.9%) |
[85] | 159 | 60 (54–67) | – | Par | RFA | 70.7% | – |
[86] | 121 | 59.8±9.7 | – | Par | RFA | – | 4.8 years (46.6%) |
[87] | 210 | 56.6±10 | 61.8±6.1 | Par/Per | RFA | 80.6% | – |
[88] | 61 | 63.4±10.5 | 67.1±6.6 | Par/Per | RFA | 96.7% | 3 years (88.5%) |
[89] | 136 | 58.2±10.8 | – | Par/Per | RFA | 57.4% | – |
[90] | 63 | 56.0±7.2 | 55.5±8.2 | Par/Per | RFA | 38.1% | 7 years (13%) |
[91] | 150 | 58.2±10 | 57.±10.8 | Par/Per | RFA | 84% | – |
[92] | 356 | 59 (51–65) | 60 (57–62) | Par/Per | RFA | ~67.5% | 5 years (45%) |
[93] | 100 | 55.7±9.6 | 70±11 | Par/Per | RFA | 40% | 5 years (29%) |
[94] | 229 | – | – | Par/Per | RFA | 77.3% | – |
[95] | 50 | 62.4±9.5 | 56.3±4.1 | Per | RFA | 54% | – |
[96] | 83 | 65±8 | 27.8±9.5 | Per | RFA | 73.5% | – |
[97] | 25 | 60±7 | 55 (50–60) | Per | RFA | 68% | – |
[98] | 49 | 64.0±8.7 | 56.8±8.1 | Per | RFA | 61.2% | – |
[99] | 67 | 58±10 | 55±11 | Per | RFA | – | 1.5 years (59%) |
[100] | 61 | 62.1±9.9 | - | Per | RFA | 54% | – |
[101] | 202 | 61±9 | 60±7 | Per | RFA | 35.1% | 4.6 years (20.3%) |
[102] | 191 | 58.2±12.9 | 57±11 | Per | RFA | – | 1.1 years (32%) |
[103] | 104 | 60.4±11.2 | 60.9±0.6 | Par | CBA | 74.6% | – |
[104] | 154 | 57.7±12.3 | 59.6±7.0 | Par | CBA | 57.1% | – |
[105] | 116 | 58.6±9.2 | 59.1±6.6 | Par | CBA | 51.7% | – |
[106] | 163 | 57±9 | 60±6 | Par | CBA | 69.9% | – |
[107] | 107 | 50.5±13.1 | 62.8±5.4 | Par | CBA | 82.2% | – |
[79] | 247 | 60.8±10.0 | 65.9±5.4 | Par | CBA | 79.8% | 2.2 years (70.9%) |
[108] | 163 | 58 (50, 64) | 62 (57, 65) | Par | CBA | 69% | 5 years (53%) |
[80] | 25 | 58±9 | 60±5 | Par | CBA | 88% | – |
[109] | 55 | 62.9±8.7 | 61.7±5.4 | Par/Per | CBA | 61.8% | – |
[81] | 101 | 62.9±8.9 | 58.0±9.0 | Par | CBA | 60.3% | – |
[82] | 136 | 57±13.3 | – | Par | CBA | – | 1.9 years (63.2%) |
[110] | 120 | 61.9±9.3 | 55.9±8.5 | Par/Per | CBA | 74.2% | – |
[111] | 1742 | 58.0±10.4 | – | Par/Per | CBA | 78.5% | – |
[112] | 100 | 66.5±9.4 | 61.5±5.6 | Par/Per | CBA | 80% | – |
[113] | 80 | 66±10 | 57±10 | Par/Per | CBA | 68% | – |
[114] | 256 | 58±10.9 | 65±6.5 | Par/Per | CBA | 85.5% | 5 years (59.4%) |
[87] | 200 | 57.5±9.8 | 61.1±7.1 | Par/Per | CBA | 72.7% | – |
[115] | 299 | 60±11 | 59±8 | Par/Per | CBA | 83.9%(Par)/61.6%(Per) | – |
[88] | 70 | 64.1±10.1 | 68.0±9.1 | Par/Per | CBA | 82.8% | 3 years (70.0%) |
[116] | 236 | 54.6±10.45 | 64.5±5.8 | Par/Per | CBA | – | 1.5 years (74.5%) |
[89] | 133 | 59.7±9.9 | – | Par/Per | CBA | 75.2% | – |
[117] | 133 | 66±10 | 51±8 | Per | CBA | 67% | – |
[118] | 49 | 63±10 | – | Per | CBA | 69% | 1.1 years (69%) |
[119] | 100 | 63±10 | 57.6±6.4 | Per | CBA | – | 0.9 years (67%) |
[95] | 50 | 62.4±9.8 | 57.5±3.7 | Per | CBA | 56% | – |
[120] | 69 | 59.4±8.1 | – | Per | CBA | 59% | 1.7 years (50%) |
[121] | 917 | – | – | Per | CBA | – | 1.4 years (68.9%) |
Abbreviations: AF, atrial fibrillation; RFA, radiofrequency ablation; PFA, pulsed field ablation; CBA, cryoballoon ablation; Par, Paroxysmal; Per, Persistent.